A tutorial for model‐based evaluation and translation of cardiovascular safety in preclinical trials
Open Access
- 23 November 2023
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (1) , 5-22
Abstract
Assessment of drug‐induced effects on the cardiovascular (CV) system remains a critical component of the drug discovery process enabling refinement of the therapeutic index. Predicting potential drug‐related unintended CV effects in the preclinical stage is necessary for first‐in‐human dose selection and preclusion of adverse CV effects in the clinical stage. According to the current guidelines for small molecules, nonclinical CV safety assessment conducted via telemetry analyses should be included in the safety pharmacology core battery studies. However, the manual for quantitative evaluation of the CV safety signals in animals is available only for electrocardiogram parameters (i.e., QT interval assessment), not for hemodynamic parameters (i.e., heart rate, blood pressure, etc.). Various model‐based approaches, including empirical pharmacokinetic‐toxicodynamic analyses and systems pharmacology modeling could be used in the framework of telemetry data evaluation. In this tutorial, we provide a comprehensive workflow for the analysis of nonclinical CV safety on hemodynamic parameters with a sequential approach, highlight the challenges associated with the data, and propose respective solutions, complemented with a reproducible example. The work is aimed at helping researchers conduct model‐based analyses of the CV safety in animals with subsequent translation of the effect to humans seamlessly and efficiently.Keywords
This publication has 54 references indexed in Scilit:
- Basic Concepts in Population Modeling, Simulation, and Model‐Based Drug Development: Part 3—Introduction to Pharmacodynamic Modeling MethodsCPT: Pharmacometrics & Systems Pharmacology, 2014
- Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and DevelopmentCPT: Pharmacometrics & Systems Pharmacology, 2013
- Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticalsExpert Opinion on Drug Safety, 2012
- Review of the statistical analysis of the dog telemetry studyPharmaceutical Statistics, 2010
- Translational pharmacokinetic–pharmacodynamic modelling; application to cardiovascular safety data for PF‐00821385, a novel HIV agentBritish Journal of Clinical Pharmacology, 2010
- Preclinical Cardiovascular Risk Assessment in Modern Drug DevelopmentToxicological Sciences, 2007
- Enterohepatic CirculationClinical Pharmacokinetics, 2002
- The time of maximum effect for model selection in pharmacokinetic– pharmacodynamic analysis applied to frusemideBritish Journal of Clinical Pharmacology, 1998
- Circadian rhythms of blood pressure, heart rate, and locomotor activity in spontaneously hypertensive rats as measured with radio-telemetryPhysiology & Behavior, 1994
- Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearanceJournal of Pharmacokinetics and Biopharmaceutics, 1977